Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANG003 in Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
NCT07450547Phase 2Recruiting
- Sponsor
- Anagram Therapeutics
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of ANG003 in exocrine pancreatic insufficiency (EPI) (5 arms), sponsored by Anagram Therapeutics. Primary endpoints: Adverse Events at 80 days and Coefficient of Fat Absorption at 72 hours. Started Apr 2026; status: recruiting.
02
Drugs
ANG003
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT07450547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450547.